CLSD(Delisted)
Clearside Biomedical·NASDAQ
--
--(--)
4.71 / 10
Netural
Analysts remain neutral (100% Neutral rating) with 33.3% historical win rate. Fund flow analysis shows 57%+ inflow ratios across all investor sizes, indicating positive capital allocation despite bankruptcy-related price collapse (-89.27% recently).
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-18
InstitutionNeedham
Times predicted6
Historical Win Rate33.3%
What is the analyst consensus for CLSD?
- CLSD holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.71/10 (Netural).
